诚益通(300430) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥159,883,887.29, representing a 200.90% increase compared to ¥53,135,142.89 in the same period last year[8]. - Net profit attributable to shareholders was ¥13,412,026.83, a significant turnaround from a loss of ¥20,682,028.95 in the previous year, marking a 164.85% increase[8]. - The net profit after deducting non-recurring gains and losses was ¥12,228,961.09, compared to a loss of ¥21,605,883.00 last year, reflecting a 156.60% improvement[8]. - Basic earnings per share increased to ¥0.05 from a loss of ¥0.08, showing a 162.50% growth[8]. - The weighted average return on equity improved to 0.76% from -1.22% year-on-year, indicating a positive trend in profitability[8]. - Operating revenue increased by 200.90% year-on-year, reaching 160 million RMB, primarily due to the recovery of project acceptance progress after the pandemic[19]. - The net profit turned positive, amounting to 13.29 million RMB, compared to a loss in the previous year[21]. - The pharmaceutical and biological intelligent manufacturing segment achieved revenue of 124 million RMB, a year-on-year increase of 231.64%[21]. - The rehabilitation medical equipment segment reported revenue of 36.17 million RMB, up 128.47% year-on-year[23]. - The company expects to achieve a net profit of RMB 45 million to RMB 58.5 million for the first half of 2021, compared to a loss of RMB 6.248 million in the same period last year, indicating a turnaround[39]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,513,682,150.62, a slight decrease of 0.41% from ¥2,523,998,565.50 at the end of the previous year[8]. - The net assets attributable to shareholders increased by 0.54% to ¥1,773,933,440.08 from ¥1,764,492,691.06[8]. - The company's total assets decreased from ¥1,996,680,384.01 to ¥1,981,420,009.83, indicating a slight contraction in asset base[58]. - Total liabilities decreased from ¥466,070,828.12 to ¥447,021,028.17, showing a reduction in financial obligations[58]. - Total liabilities decreased from CNY 738,168,339.13 to CNY 718,537,826.57, a decline of approximately 2.6%[51]. Cash Flow - The company reported a net cash flow from operating activities of -¥70,571,036.50, which is a 2.99% decline compared to -¥68,523,709.46 in the previous year[8]. - Cash inflow from operating activities amounted to CNY 184,753,234.67, up from CNY 125,682,261.65 in the previous period, representing an increase of approximately 47%[67]. - Net cash flow from operating activities was negative at CNY -70,571,036.50, slightly worse than the previous period's CNY -68,523,709.46[67]. - Cash outflow from investing activities totaled CNY 171,929,651.59, significantly higher than CNY 45,897,911.04 in the previous period[67]. - Net cash flow from investing activities was CNY -75,029,343.52, compared to a positive CNY 3,909,278.12 in the previous period[67]. - Cash inflow from financing activities was CNY 71,957,901.82, an increase from CNY 53,941,827.93 in the previous period[68]. - Net cash flow from financing activities was CNY 16,585,912.18, down from CNY 20,959,433.86 in the previous period[68]. - The ending balance of cash and cash equivalents was CNY 90,084,031.13, compared to CNY 60,070,863.76 at the end of the previous period[68]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,408[12]. - A cash dividend of 0.16 RMB per share is proposed, totaling approximately 4.35 million RMB, subject to shareholder approval[31]. - The company plans to repurchase shares with a budget between RMB 20 million and RMB 40 million, with a maximum price of RMB 11.00 per share, and has already repurchased 530,900 shares, accounting for 0.20% of total shares[33]. Business Development - The company plans to enhance its core competitiveness by expanding into new markets and strengthening R&D capabilities[28]. - New signed and awarded contracts amount to RMB 203 million, representing a 50.01% increase compared to the same period last year[40]. - The company is actively expanding its business in the pharmaceutical and biomedical intelligent manufacturing sectors, focusing on areas such as chemical synthesis and traditional Chinese medicine[40]. - The company has successfully completed the acquisition of 100% equity in Guangzhou Longzhijie, with a total investment of RMB 11,934.72 million, achieving 100% of the planned investment[37]. - The company has made significant progress in the rehabilitation medical equipment sector, with demand recovering as the pandemic situation improves[40]. Other Information - The company received government subsidies amounting to ¥1,471,391.38 during the reporting period[9]. - The company has not encountered any overdue commitments from major stakeholders during the reporting period[35]. - The company has not reported any major changes in the feasibility of its projects during the reporting period[38]. - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[43]. - There were no violations regarding external guarantees during the reporting period[42]. - The company has not undergone an audit for the first quarter report[73].